Literature DB >> 29222404

Lack of Parkin Anticipates the Phenotype and Affects Mitochondrial Morphology and mtDNA Levels in a Mouse Model of Parkinson's Disease.

Milena Pinto1, Nadee Nissanka2, Carlos T Moraes1,2.   

Abstract

PARK2 is the most common gene mutated in monogenic recessive familial cases of Parkinson's disease (PD). Pathogenic mutations cause a loss of function of the encoded protein Parkin. ParkinKO mice, however, poorly represent human PD symptoms as they only exhibit mild motor phenotypes, minor dopamine metabolism abnormalities, and no signs of dopaminergic neurodegeneration. Parkin has been shown to participate in mitochondrial turnover, by targeting damaged mitochondria with low membrane potential to mitophagy. We studied the role of Parkin on mitochondrial quality control in vivo by knocking out Parkin in the PD-mito-PstI mouse (males), where the mitochondrial DNA (mtDNA) undergoes double-strand breaks only in dopaminergic neurons. The lack of Parkin promoted earlier onset of dopaminergic neurodegeneration and motor defects in the PD-mito-PstI mice, but it did not worsen the pathology. The lack of Parkin affected mitochondrial morphology in dopaminergic axons and was associated with an increase in mtDNA levels (mutant and wild type). Unexpectedly, it did not cause a parallel increase in mitochondrial mass or mitophagy. Our results suggest that Parkin affects mtDNA levels in a mitophagy-independent manner.SIGNIFICANCE STATEMENT Parkinson's disease is characterized by progressive motor symptoms due to the selective loss of dopaminergic neurons in the substantia nigra. Loss-of-function mutations of Parkin cause some monogenic forms of Parkinson's disease, possibly through its role in mitochondrial turnover and quality control. To study whether Parkin has a role in vivo in the context of mitochondrial damage, we knocked out Parkin in a mouse model in which the mitochondrial DNA is damaged in dopaminergic neurons. We found that the loss of Parkin did not exacerbate the parkinsonian pathology already present in the mice, but it was associated with an increase in mtDNA levels (mutant and wild-type) without altering mitochondrial mass. These results shed new light on the function of Parkin in vivo.
Copyright © 2018 the authors 0270-6474/18/381042-12$15.00/0.

Entities:  

Keywords:  Parkinson; deletion; double-strand breaks; mitochondria; mitophagy; mtDNA

Mesh:

Substances:

Year:  2017        PMID: 29222404      PMCID: PMC5783961          DOI: 10.1523/JNEUROSCI.1384-17.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  70 in total

1.  Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion.

Authors:  K Matsuura; H Kabuto; H Makino; N Ogawa
Journal:  J Neurosci Methods       Date:  1997-04-25       Impact factor: 2.390

2.  Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells.

Authors:  Der-Fen Suen; Derek P Narendra; Atsushi Tanaka; Giovanni Manfredi; Richard J Youle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

3.  PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease.

Authors:  Joo-Ho Shin; Han Seok Ko; Hochul Kang; Yunjong Lee; Yun-Il Lee; Olga Pletinkova; Juan C Troconso; Valina L Dawson; Ted M Dawson
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 4.  The role of mitochondria in aging.

Authors:  Ana Bratic; Nils-Göran Larsson
Journal:  J Clin Invest       Date:  2013-03-01       Impact factor: 14.808

5.  Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells.

Authors:  Kye-Young Kim; Mark V Stevens; M Hasina Akter; Sarah E Rusk; Robert J Huang; Alexandra Cohen; Audrey Noguchi; Danielle Springer; Alexander V Bocharov; Tomas L Eggerman; Der-Fen Suen; Richard J Youle; Marcelo Amar; Alan T Remaley; Michael N Sack
Journal:  J Clin Invest       Date:  2011-08-25       Impact factor: 14.808

6.  Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease.

Authors:  A H Schapira; V M Mann; J M Cooper; D Dexter; S E Daniel; P Jenner; J B Clark; C D Marsden
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

7.  Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio).

Authors:  Laura Flinn; Heather Mortiboys; Katrin Volkmann; Reinhard W Köster; Phillip W Ingham; Oliver Bandmann
Journal:  Brain       Date:  2009-05-12       Impact factor: 13.501

8.  Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations.

Authors:  Hsiuchen Chen; Marc Vermulst; Yun E Wang; Anne Chomyn; Tomas A Prolla; J Michael McCaffery; David C Chan
Journal:  Cell       Date:  2010-04-16       Impact factor: 41.582

9.  Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage.

Authors:  Yusuke Kageyama; Zhongyan Zhang; Ricardo Roda; Masahiro Fukaya; Junko Wakabayashi; Nobunao Wakabayashi; Thomas W Kensler; P Hemachandra Reddy; Miho Iijima; Hiromi Sesaki
Journal:  J Cell Biol       Date:  2012-05-07       Impact factor: 10.539

10.  Mitochondrial DNA Depletion in Respiratory Chain-Deficient Parkinson Disease Neurons.

Authors:  Anne Grünewald; Karolina A Rygiel; Philippa D Hepplewhite; Christopher M Morris; Martin Picard; Doug M Turnbull
Journal:  Ann Neurol       Date:  2016-01-28       Impact factor: 10.422

View more
  15 in total

Review 1.  Regulation of Mitochondrial ATP Production: Ca2+ Signaling and Quality Control.

Authors:  Liron Boyman; Mariusz Karbowski; W Jonathan Lederer
Journal:  Trends Mol Med       Date:  2019-11-22       Impact factor: 11.951

2.  Image-Based Analysis of Mitochondrial Area and Counting from Adult Mouse Dopaminergic Neurites.

Authors:  Nadee Nissanka; Carlos T Moraes; Milena Pinto
Journal:  Bio Protoc       Date:  2018-08-20

3.  Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats.

Authors:  Sanaa Ahmed; Mahmoud M El-Sayed; Mohamed A Kandeil; Marwa M Khalaf
Journal:  Saudi Pharm J       Date:  2022-03-16       Impact factor: 4.562

Review 4.  The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.

Authors:  Margrethe A Olesen; Francisca Villavicencio-Tejo; Rodrigo A Quintanilla
Journal:  Transl Neurodegener       Date:  2022-07-04       Impact factor: 9.883

Review 5.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

6.  MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation.

Authors:  Sandra R Bacman; Johanna H K Kauppila; Claudia V Pereira; Nadee Nissanka; Maria Miranda; Milena Pinto; Sion L Williams; Nils-Göran Larsson; James B Stewart; Carlos T Moraes
Journal:  Nat Med       Date:  2018-09-24       Impact factor: 53.440

7.  PARK2 Mutation Causes Metabolic Disturbances and Impaired Survival of Human iPSC-Derived Neurons.

Authors:  Helle Bogetofte; Pia Jensen; Matias Ryding; Sissel I Schmidt; Justyna Okarmus; Louise Ritter; Christina S Worm; Michaela C Hohnholt; Carla Azevedo; Laurent Roybon; Lasse K Bak; Helle Waagepetersen; Brent J Ryan; Richard Wade-Martins; Martin R Larsen; Morten Meyer
Journal:  Front Cell Neurosci       Date:  2019-07-05       Impact factor: 5.505

8.  PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.

Authors:  Sheila K Pirooznia; Changqing Yuan; Mohammed Repon Khan; Senthilkumar S Karuppagounder; Luan Wang; Yulan Xiong; Sung Ung Kang; Yunjong Lee; Valina L Dawson; Ted M Dawson
Journal:  Mol Neurodegener       Date:  2020-03-05       Impact factor: 14.195

Review 9.  Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson's Disease.

Authors:  Xiao-Le Wang; Si-Tong Feng; Zhen-Zhen Wang; Yu-He Yuan; Nai-Hong Chen; Yi Zhang
Journal:  Cell Mol Neurobiol       Date:  2020-07-04       Impact factor: 5.046

Review 10.  Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing.

Authors:  Hammad Ullah; Haroon Khan
Journal:  Front Pharmacol       Date:  2018-04-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.